Prof. Michael Roden
Professor Michael Roden is Chair of Endocrinology and Metabolic Diseases, Heinrich-Heine University, Director of the Division of Endocrinology and Diabetology, University Clinics Düsseldorf and CEO of the German Diabetes Center (DDZ). He was trained at University of Vienna and Yale University. His translational studies..
PPAR’S AS CRITICAL REGULATORS OF METABOLISM
The prevalence of NAFLD is increasing worldwide in parallel with the rising epidemics of obesity and T2DM. NASH is now becoming one of the main causes of Cirrhosis and HCC and the main indication for liver transplantation. Except for lifestyle modification through diet and exercise, there are currently no approved treatments for NASH. While bariatric surgery can be considered in otherwise eligible patients with NAFLD or NASH, it is premature to consider it as an established option for the treatment of NASH. Numerous novel treatments for NASH are currently in development targeting metabolism, cell death, inflammation, fibrosis and the gut-liver axis. However, drugs focusing on just one target may not be sufficiently efficacious and might have to be used in combination. That being said, Pan-PPAR agonists that act on multiple targets may be a promising new therapeutic option for NASH.
Read MorePPAR’S AS CRITICAL REGULATORS OF METABOLISM
PPAR’s as Critical Regulators of Metabolism
Prof Roden, Germany explains why PPAR’s are interesting therapeutic targets not only to improve adipose tissue function but also for the liver. The approach can go beyond the improvement of liver function and aim at a more systemic approach with cardiovascular benefits.
Read MorePPAR’s as Critical Regulators of MetabolismNAFLD and states of insulin resistance
Insulin resistance is tightly linked to NAFLD, particularly in those with Type 2 Diabetes.
In this video, Prof. Michael Roden, Germany discusses this link, its origins that can inherited or acquired. He also sheds light on the consequences of insulin resistance.
Read MoreNAFLD and states of insulin resistance
Why are NASH patients at increased CV risk & how can PPAR agonists potentially improve outcomes?
Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.
Read MoreWhy are NASH patients at increased CV risk & how can PPAR agonists potentially improve outcomes?
Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston
So this year’s meeting of the AASLD in Boston specifically…
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES